Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.50 |
| ▸ | MAOA | P21397 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 3/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27217655 | 1.00 | PARP1 (0.50) | PARP1MAOAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL10831325 | 0.80 | PARP1 (0.51) | PARP1MAOAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL29017447 | 0.79 | PARP1 (0.36) | PARP1MAOAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL27847940 | 0.79 | PARP1 (0.50) | PARP1MAOAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL31634103 | 0.74 | RXFP1 (0.30) | — | |
| SCHEMBL10320307 | 0.73 | PARP1 (0.64) | PARP1MAOAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL15666675 | 0.72 | MAOA (0.46) | PARP1MAOAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL15667395 | 0.72 | MAOA (0.46) | PARP1MAOAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL15666673 | 0.72 | MAOA (0.46) | PARP1MAOAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL18181654 | 0.72 | MAOA (0.42) | PARP1MAOAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| EP-3287463-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016169504-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | 广州再极医药科技有限公司 | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | PDK1, WEE1, DCK | PARP1 129/4885MAOA 1258/4885KDM4E 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.